GlassScriptPhysician profile
Rushikesh Shah
NPI 1144578378
$35,126.87
in general payments reported to CMS, 2019-2025
31 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.77 · 2020: $927 · 2021: $1,657 · 2022: $1,934 · 2023: $2,260 · 2024: $13K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $9,010 · Food and Beverage: $7,269 · Travel and Lodging: $2,253 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,875.00 |
| Consulting Fee | $9,010.00 |
| Food and Beverage | $7,268.69 |
| Travel and Lodging | $2,253.14 |
| Education | $170.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,176.00 | 2020-2025 | Linzess, Viberzi, Creon |
| W. L. Gore & Associates, INC. | $10,192.71 | 2024 | Gore Viabil Biliary Endoprosthesis |
| Boston Scientific Corporation | $2,461.71 | 2021-2025 | Resolution 360 Clip, Exalt Model D, Axios |
| Conmed Corporation | $1,146.33 | 2021-2025 | Conmed Biliary, Conmed Dilation, System 2450 |
| Endogastric Solutions, INC | $890.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $700.15 | 2020-2025 | Gattex, Entyvio, Eohilia |
| Janssen Biotech, INC. | $396.87 | 2021-2025 | Tremfya, Stelara |
| Cook Medical LLC | $307.68 | 2021-2025 | Echotip Insight |
| Genzyme Corporation | $219.50 | 2022-2025 | |
| 3-D Matrix, INC. | $156.38 | 2024 | |
| Ferring Pharmaceuticals INC. | $155.56 | 2021-2024 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.53 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Erbe USA INC | $100.00 | 2025 | Vio3 |
| Aimmune Therapeutics, INC. | $95.86 | 2023-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $95.62 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.98 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $88.86 | 2022-2023 | Ocaliva |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Redhill Biopharma INC. | $78.81 | 2021-2022 | |
| Braintree Laboratories, INC. | $72.29 | 2021-2023 | Sutab, Suflave |
| Vivus LLC | $69.31 | 2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $68.54 | 2023 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $67.29 | 2023 | Endorotor |
| Qol Medical, LLC | $66.19 | 2020-2022 | |
| Ardelyx, INC. | $59.95 | 2022-2025 | Ibsrela |
| Pfizer INC. | $57.78 | 2021-2025 | |
| Madrigal Pharmaceuticals | $22.30 | 2024 | Resmetirom |
| Phathom Pharmaceuticals, INC. | $19.85 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $19.44 | 2022 | |
| Olympus America INC. | $11.91 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,968.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushikesh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.